Opendata, web and dolomites

GlioTarget SIGNED

Inflaming the microenvironment of glioblastoma tumors by ADAR1 inhibition: a two-hit approach for the treatment of brain cancer.

Total Cost €


EC-Contrib. €






 GlioTarget project word cloud

Explore the words cloud of the GlioTarget project. It provides you a very rough idea of what is the project "GlioTarget" about.

cells    orchestrate    patient    disheartening    genes    sensitivity    hinder    primary    fail    experiences    expressing    precious    date    infiltration    adar1    functionally    newly    nucleic    otherwise    median    combine    representing    15    interactions    aberrant    oncology    alone    foreign    innate    sensing    immuno    body    supporting    inflammation    14    human    heterogeneity    outcomes    nature    deaminase    disrupt    care    ultimately    survival    despite    standard    molecular    expression    adenosine    cell    form    trigger    tumors    invariably    microenvironment    stores    inhibit    checkpoint    understand    pointing    patients    therapy    mouse    arrest    memories    immune    malignancies    vulnerability    lines    tumor    frequent    simultaneously    extreme    endogenous    clinical    genetic    diagnosed    leads    social    emerged    gbs    isg    acting    acids    stimulated    functions    glioblastomas    immunity    combination    organ    individuals    dsrnas    immunosuppressive    vital    months    edits    core    gb    perform    rna    pharmacologic    central    interferon    models    cancer    tme    immunotherapies    lethal    therapies    therapeutic    brain    self    isgs    inhibition   

Project "GlioTarget" data sheet

The following table provides information about the project.


Organization address
address: Quartier Unil-Centre Bâtiment Unicentre
postcode: 1015

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Switzerland [CH]
 Total cost 191˙149 €
 EC max contribution 191˙149 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2021
 Duration (year-month-day) from 2021-09-01   to  2023-08-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITE DE LAUSANNE CH (LAUSANNE) coordinator 191˙149.00


 Project objective

The brain is our most precious organ. Not only does it orchestrate vital body functions but it also stores memories and experiences, ultimately defining the core of our human nature. Brain malignancies are particularly disheartening because they disrupt our ability to perform as individuals and hinder our social interactions. Glioblastomas (GBs) represent the most frequent and lethal form of primary brain tumors, with a median survival of 14.6 months and 15,000 newly diagnosed patients per year in Europe and the US. Current therapies invariably fail, likely due to the extreme genetic heterogeneity of GB and the presence of a highly immunosuppressive tumor microenvironment (TME). Here, I propose to exploit an innate immunity checkpoint to simultaneously target cancer cells and their supporting TME. Adenosine Deaminase Acting on RNA 1 (ADAR1) is a central component of the RNA sensing pathway. It edits endogenous self dsRNAs, which would otherwise be recognized as foreign and trigger an aberrant innate immune response. Sensing of foreign nucleic acids results in interferon production which leads to cell-growth arrest, inflammation and immune cell infiltration through the expression of interferon-stimulated genes (ISGs). ADAR1 has recently emerged as a promising immuno-oncology target, with evidence pointing towards ADAR1 loss representing a novel vulnerability of ISG-expressing cancer cells. Despite expressing ISGs, GB tumors have not been evaluated for sensitivity to ADAR1 inhibition to date. I will therefore combine genetic and pharmacologic approaches to inhibit ADAR1 in patient-derived cancer cell lines and pre-clinical mouse models of GB. My aims are: i) to understand the molecular outcomes of ADAR1 inhibition in GB cancer cells; ii) to functionally characterize the TME of GBs upon ADAR1 inhibition; iii) to evaluate the therapeutic potential of ADAR1 inhibition alone and in combination with standard of care therapy and TME-targeted immunotherapies.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLIOTARGET" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLIOTARGET" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

InProSMod (2021)

Cholinergic and NMDAR-dependent recruitment of Layer 1 Interneuron shapes cortical motor Processing through network States Modulation

Read More  

STIMOS (2019)

Stimulation of Multiple Organoids Simultaneously

Read More  


Digital Poetry in Today’s Russia: Canonisation and Translation

Read More  
lastchecktime (2022-10-03 2:45:51) correctly updated